JPRN-UMIN000014129
Completed
未知
Assessment of safety and effectiveness: the clinical use of tofogliflozin in patients with type 2 diabetes mellitus - AYUMI
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Japan Association for Diabetes Education and Care
- Enrollment
- 10000
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Hypersensitivity to tofogliflozin 2\.Patients who had severe ketosis or diabetic coma or precoma 3\.Severe infection or trauma, perioperative 4\.End stage renal disease with hemodialysis or peritoneal dialysis 5\.Patients whose participation is deemed inappropriate at the discretion of the attending physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinical Evaluation of the Safety and Effectiveness of Harvest Autologous Platelet Concentrate and Harvest Autologous Thrombin for Treatment of Lower Extremity Chronic Diabetic UlcersISRCTN28965380Harvest Technologies Corp. (USA)59
Active, not recruiting
Not Applicable
Evaluación de la eficacia clinica, seguridad y actividad farmacologica de UR-1505 en voluntarios con alergia a niquel: estudio aleatorizado, doble ciego, cruzado y con control activoVolunteers with nickel allergyEUCTR2005-005677-30-ESJ. Uriach y Compañia, S. A.40
Recruiting
Phase 3
comparision of efficacy of intradermal tranxamic acid injection with fractional Q-Switch Nd-yag laser for melasma treatmentIRCT20180418039349N1Skin and Stem Cell Research Center28
Withdrawn
Not Applicable
Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients with Hypertension: A Double-Blind Randomized Trialhigh blood pressureHypertension1000752110057166NL-OMON46157BackBeat Medical, Inc.10
Recruiting
Not Applicable
An observational study to evaluate safety and effectiveness of hydrophilic acrylic intraocular lens.Health Condition 1: H259- Unspecified age-related cataractCTRI/2021/11/037924Carl Zeiss Meditec AG